SEGMENT INFORMATION (Tables)

6 Months Ended

Jun. 30, 2026

SEGMENT INFORMATION

Schedule of Segment Information

b. Segment information:

	Six Months Ended June 30,				Three Months Ended June 30,
(U.S. dollars in thousands)	2026		2025		2026		2025
Revenues from customers	$	53,646	$	25,771	$	19,896	$	15,658
Less:
Employee salaries and related expenses		14,352		10,649		7,655		5,444
Sub-contractors expense		8,340		7,463		3,899		4,773
Interest expense		-		-		-		-
Interest income		(848)		(528)		(660)		(272)
Depreciation		810		706		406		360
R&D grant		(2,100)				(2,100)
Other segment expenses, net*		7,091		10,552		5,836		4,692
Income (loss) before taxes on income		26,001		(3,071)		4,860		661
Taxes on income		3,907		384		1,083		497
Segment net income (loss)	$	22,094	$	(3,455)	$	3,777	$	164

* Other expenses included in net income include raw materials, rent, and utilities, and others.

Schedule of Disaggregation of Revenues

c. The following table summarizes the Company’s disaggregation of revenues:

	Six Months Ended June 30,				Three Months Ended June 30,
(U.S. dollars in thousands)	2026		2025		2026		2025
Gaucher disease:
Pfizer (Ireland)	$	5,731	$	12,626	$	4,279	$	5,647
Fiocruz (Brazil)	$	3,968	$	3,016	$	1,514	$	-
Fabry disease:
Chiesi (Italy)	$	17,548	$	9,793	$	14,035	$	9,793
Total revenues from selling goods	$	27,247	$	25,435	$	19,828	$	15,440
Revenues from license and R&D services	$	26,399	$	336	$	68	$	218